These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases. Lipskaia L; Hadri L; Lopez JJ; Hajjar RJ; Bobe R Curr Vasc Pharmacol; 2013 Jul; 11(4):465-79. PubMed ID: 23905641 [TBL] [Abstract][Full Text] [Related]
7. Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure. Papolos A; Frishman WH Cardiol Rev; 2013; 21(3):151-4. PubMed ID: 23568057 [TBL] [Abstract][Full Text] [Related]
8. Gene therapy for heart failure. Greenberg B J Cardiol; 2015 Sep; 66(3):195-200. PubMed ID: 25818479 [TBL] [Abstract][Full Text] [Related]
9. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121 [TBL] [Abstract][Full Text] [Related]
15. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. del Monte F; Williams E; Lebeche D; Schmidt U; Rosenzweig A; Gwathmey JK; Lewandowski ED; Hajjar RJ Circulation; 2001 Sep; 104(12):1424-9. PubMed ID: 11560860 [TBL] [Abstract][Full Text] [Related]